140 filings
8-K
FGEN
FibroGen Inc
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
8-K
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
FGEN
FibroGen Inc
27 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
FGEN
FibroGen Inc
5 Oct 23
Departure of Directors or Certain Officers
7:41pm
8-K
19w1efrn
6 Sep 23
Departure of Directors or Certain Officers
8:55am
8-K
8i98k
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
9dmv0
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
s9iv78
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
bvj 6lmjw9w11ff
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
4n5rkuyltmaq1rqb6
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
kl8hiqln 6fc
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
q275otw7
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
hxoy4cv
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
fr9vms pvbq8
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm
8-K
r8kcvpg03hhuy
1 May 23
Entry into a Material Definitive Agreement
4:48pm
8-K
y2eokt0d6
27 Feb 23
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
4:06pm
8-K
993995h4m9i
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm
8-K
gt3e7zczifd5 l3be
8 Aug 22
FibroGen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
a76884qjelzirg3nt7
17 Jun 22
Submission of Matters to a Vote of Security Holders
5:20pm